JSKN022 in Subjects With Advanced Malignant Solid Tumors

Summary

The goal of this clinical trial is to learn if drug JSKN022 is safe to treat patients with advanced malignant solid tumors. It will also learn about the pharmacokinetic/ pharmacodynamic profiles and preliminary antitumor activity of drug JSKN022.

Timeline

Start

2025-10-23

Primary completion

2027-08-31

Completion

2027-12-31

Drugs

Indications